A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carmot Therapeutics, Inc.
• Collaborator: Carmot Australia First Pty Ltd

Criteria

Inclusion Criteria:

• Males or females

• 18-65 years old, inclusive

• BMI 27.0-40.0, inclusive

• Stable body weight for 2 months

Exclusion Criteria:

• Significant medical history

• Uncontrolled hypertension

• History of malignancy